Palisade Bio (PALI) Price & Analysis

Compare

555 Followers

PALI Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.55 - $4.32

Previous CloseN/A

Volume307.14K

Average Volume (3M)3.91M

Market Cap

$5.21M

Enterprise Value-$1.81M

Total Cash (Recent Filing)$5.42M

Total Debt (Recent Filing)$24.00K

Price to Earnings (P/E)―

Beta0.20

Next Earnings

Nov 17, 2025

EPS Estimate

-0.38

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.58

Shares Outstanding9,119,152

10 Day Avg. Volume832,590

30 Day Avg. Volume3,906,154

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap-0.35

Enterprise Value/Revenue-453.61

Enterprise Value/Gross Profit1.81K

Enterprise Value/Ebitda0.15

Forecast

1Y Price Target

$2.00

Price Target Upside257.14% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Bulls Say, Bears Say

Bulls Say

Clinical Trial ResultsPalisade announced additional highly positive data from the Phase 1b trial of PALI-2108, showing 100% clinical response in ulcerative colitis patients.

Market PotentialManagement plans to evaluate PALI-2108 specifically for fibrostenotic Crohn’s disease, a large market with no current FDA approved therapies, making it an attractive focus area.

Safety ProfilePALI-2108 was found to be well-tolerated with no serious adverse events, suggesting safety alongside its effectiveness.

Bears Say

Financing NeedsThe analyst's recommendation includes a lower 12-month price target due to expected dilution from future financing needs.

Market DynamicsPalisade Bio will require another financing following the data, which may be more dilutive given the current market dynamics.

Palisade Bio News

Palisade Bio receives Health Canada clearance for Phase 1b PALI-2108 trial

Palisade Bio (PALI) received a No Objection Letter from Health Canada for its Clinical Trial Application to evaluate...

6d ago

PALI

Palisade Bio releases virtual KOL Connect segment on PALI-2108

Palisade Bio (PALI) announced the release of a Virtual Investor KOL Connect segment featuring Dr. Brian G. Feagan,...

17d ago

PALI

Palisade Bio files to sell 8.9M shares of common stock for holders

16:08 EDT Palisade Bio (PALI) files to sell 8.9M shares of common stock for holders Published first on...

26d ago

PALI

Palisade Bio Launches Phantom Unit Plan for Employees

Palisade Bio ( ($PALI) ) has shared an update. On September 4, 2025, Palisade Bio, Inc. introduced a...

6d ago

PALI

Palisade Bio: Buy Rating Backed by Financial Stability and Promising Clinical Trial Results

Analyst Naz Rahman from Maxim Group reiterated a Buy rating on Palisade Bio and keeping the price target...

20d ago

PALI

Palisade Bio’s Strategic Positioning and Promising Trial Results Earn Buy Rating

Palisade Bio, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Naz Rahman from...

1M ago

PALI

Palisade Bio’s PALI-2108: A Promising New Treatment for Ulcerative Colitis

Palisade Bio, Inc. (($PALI)) announced an update on their ongoing clinical study. Study Overview: Palisade Bio, Inc. has...

1M ago

PALI

Palisade Bio announces new data from ongoing program evaluating PALI-2108

Palisade Bio (PALI) announced compelling new data from its ongoing clinical program evaluating PALI-2108, a first-in-class, ileocolonic-targeted PDE4...

1M ago

PALI

Palisade Bio receives notice of allowance for patent of PALI-2108 in China

Palisade Bio (PALI) announced that the China National Intellectual Property Administration has issued a Notice of Allowance for...

1M ago

PALI

Palisade Bio’s Phase 1 Study on PALI-2108: A New Hope for Ulcerative Colitis Treatment

Palisade Bio, Inc. (($PALI)) announced an update on their ongoing clinical study. Study Overview: Palisade Bio, Inc. has...

1M ago

PALI

Palisade Bio Enters Warrant Inducement Agreement

Palisade Bio ( ($PALI) ) has shared an update. On July 23, 2025, Palisade Bio entered into a...

2M ago

PALI

Palisade Bio Appoints Emil Chuang as New Director

Palisade Bio ( ($PALI) ) has provided an announcement. Palisade Bio Inc. announced the resignation of Margery Fischbein...

2M ago

PALI

Palisade Bio appoints to its Board of Directors

Palisade Bio (PALI) announced it has appointed Emil Chuang to its Board of Directors. Chuang is a pediatric...

2M ago

PALI

Palisade Bio Reports Improved Quarterly Losses

Palisade Bio, Inc. ( ($PALI) ) has released its Q1 earnings. Here is a breakdown of the information...

3M ago

PALI

PALI FAQ

What was Palisade Bio, Inc.’s price range in the past 12 months?

Palisade Bio, Inc. lowest stock price was $0.55 and its highest was $4.32 in the past 12 months.

What is Palisade Bio, Inc.’s market cap?

Palisade Bio, Inc.’s market cap is $5.21M.

When is Palisade Bio, Inc.’s upcoming earnings report date?

Palisade Bio, Inc.’s upcoming earnings report date is Nov 17, 2025 which is in 67 days.

How were Palisade Bio, Inc.’s earnings last quarter?

Palisade Bio, Inc. released its earnings results on Aug 19, 2025. The company reported -$0.58 earnings per share for the quarter, beating the consensus estimate of -$0.594 by $0.014.

Is Palisade Bio, Inc. overvalued?

According to Wall Street analysts Palisade Bio, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Palisade Bio, Inc. pay dividends?

Palisade Bio, Inc. does not currently pay dividends.

What is Palisade Bio, Inc.’s EPS estimate?

Palisade Bio, Inc.’s EPS estimate is -0.38.

How many shares outstanding does Palisade Bio, Inc. have?

Palisade Bio, Inc. has 9,119,152 shares outstanding.

What happened to Palisade Bio, Inc.’s price movement after its last earnings report?

Palisade Bio, Inc. reported an EPS of -$0.58 in its last earnings report, beating expectations of -$0.594. Following the earnings report the stock price went down -2.5%.

Which hedge fund is a major shareholder of Palisade Bio, Inc.?

Currently, no hedge funds are holding shares in PALI

Company Description

Palisade Bio, Inc.

Palisade Bio (PALI) is a biopharmaceutical company focused on developing therapeutics that protect the integrity of the intestinal barrier. The company's core product candidates are designed to address unmet medical needs in the fields of gastrointestinal health, specifically targeting conditions such as inflammatory bowel disease (IBD) and postoperative digestive complications. Utilizing its proprietary technology, Palisade Bio aims to create innovative treatments that improve patient outcomes and quality of life.

Palisade Bio (PALI) Earnings & Revenues

Historic Earnings Reports

PALI Stock 12 Month Forecast

Average Price Target

$2.00

▲(257.14% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","-1":"-$1","1.25":"$1.25","3.5":"$3.5","5.75":"$5.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$2.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$2.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1.25,3.5,5.75,8],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Mar<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.01,1.0861538461538462,1.1623076923076923,1.2384615384615385,1.3146153846153847,1.3907692307692308,1.466923076923077,1.543076923076923,1.6192307692307693,1.6953846153846155,1.7715384615384615,1.8476923076923077,1.9238461538461538,{"y":2,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.01,1.0861538461538462,1.1623076923076923,1.2384615384615385,1.3146153846153847,1.3907692307692308,1.466923076923077,1.543076923076923,1.6192307692307693,1.6953846153846155,1.7715384615384615,1.8476923076923077,1.9238461538461538,{"y":2,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.01,1.0861538461538462,1.1623076923076923,1.2384615384615385,1.3146153846153847,1.3907692307692308,1.466923076923077,1.543076923076923,1.6192307692307693,1.6953846153846155,1.7715384615384615,1.8476923076923077,1.9238461538461538,{"y":2,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.12,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.85,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.08,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.65,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.53,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.45,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.77,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.4,"date":1733011200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.65,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.83,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.67,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.78,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.01,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >